| Alalia Berry, MD | |
|
2358 Nw Kings Blvd Ste 100, Corvallis, OR 97330-4687 | |
| (503) 362-8385 | |
| (503) 362-8435 |
| Full Name | Alalia Berry |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 14 Years |
| Location | 2358 Nw Kings Blvd Ste 100, Corvallis, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346566395 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207KI0005X | Allergy & Immunology - Clinical & Laboratory Immunology | 1346566395 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Macneal Hospital | Berwyn, IL | Hospital |
| Samaritan Pacific Community Hospital | Newport, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Silver Falls Dermatology Llc | 5890863492 | 84 |
News Archive
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center and SUNY Downstate Medical Center has revealed the roots of a common type of childhood asthma, showing that it is very different from other asthma cases.
Despite technological advances, discrimination against consumers inhibited by disabilities or disadvantaged by personal circumstances remains a significant problem. Many people today find themselves excluded by mainstream, day-to-day services on which they rely, such as banks, utilities, telecoms, health services and local authority providers. Their vulnerability can be hidden, a consequence of personal trauma or a health condition, or temporary resulting from a job loss. These are complex issues for organizations to identify and respond to appropriately.
SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production.
A $2.5 million federal grant will allow a multidisciplinary team at The University of Texas Health Science Center at Houston to provide prevention and treatment information about HIV, AIDS and sexually transmitted diseases to underserved individuals with substance abuse or mental disorders.
› Verified 6 days ago
| Entity Name | Allergy & Asthma Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205998663 PECOS PAC ID: 0840286928 Enrollment ID: O20040423000211 |
News Archive
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center and SUNY Downstate Medical Center has revealed the roots of a common type of childhood asthma, showing that it is very different from other asthma cases.
Despite technological advances, discrimination against consumers inhibited by disabilities or disadvantaged by personal circumstances remains a significant problem. Many people today find themselves excluded by mainstream, day-to-day services on which they rely, such as banks, utilities, telecoms, health services and local authority providers. Their vulnerability can be hidden, a consequence of personal trauma or a health condition, or temporary resulting from a job loss. These are complex issues for organizations to identify and respond to appropriately.
SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production.
A $2.5 million federal grant will allow a multidisciplinary team at The University of Texas Health Science Center at Houston to provide prevention and treatment information about HIV, AIDS and sexually transmitted diseases to underserved individuals with substance abuse or mental disorders.
› Verified 6 days ago
| Entity Name | Silver Falls Dermatology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134375421 PECOS PAC ID: 5890863492 Enrollment ID: O20081009000466 |
News Archive
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center and SUNY Downstate Medical Center has revealed the roots of a common type of childhood asthma, showing that it is very different from other asthma cases.
Despite technological advances, discrimination against consumers inhibited by disabilities or disadvantaged by personal circumstances remains a significant problem. Many people today find themselves excluded by mainstream, day-to-day services on which they rely, such as banks, utilities, telecoms, health services and local authority providers. Their vulnerability can be hidden, a consequence of personal trauma or a health condition, or temporary resulting from a job loss. These are complex issues for organizations to identify and respond to appropriately.
SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production.
A $2.5 million federal grant will allow a multidisciplinary team at The University of Texas Health Science Center at Houston to provide prevention and treatment information about HIV, AIDS and sexually transmitted diseases to underserved individuals with substance abuse or mental disorders.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alalia Berry, MD 1793 13th St Se, Salem, OR 97302-2541 Ph: (503) 362-8385 | Alalia Berry, MD 2358 Nw Kings Blvd Ste 100, Corvallis, OR 97330-4687 Ph: (503) 362-8385 |
News Archive
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center and SUNY Downstate Medical Center has revealed the roots of a common type of childhood asthma, showing that it is very different from other asthma cases.
Despite technological advances, discrimination against consumers inhibited by disabilities or disadvantaged by personal circumstances remains a significant problem. Many people today find themselves excluded by mainstream, day-to-day services on which they rely, such as banks, utilities, telecoms, health services and local authority providers. Their vulnerability can be hidden, a consequence of personal trauma or a health condition, or temporary resulting from a job loss. These are complex issues for organizations to identify and respond to appropriately.
SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production.
A $2.5 million federal grant will allow a multidisciplinary team at The University of Texas Health Science Center at Houston to provide prevention and treatment information about HIV, AIDS and sexually transmitted diseases to underserved individuals with substance abuse or mental disorders.
› Verified 6 days ago